Stay updated with the latest insights from CardioVascular Global - including clinical studies, new treatment approaches, and international collaborations.
March 31, 2026
CHAMPION AF is the first large randomized trial comparing left atrial appendage (LAA) closure with DOAC therapy in patients eligible for anticoagulation. The trial met its primary endpoints — …
March 23, 2026
The CLOSURE-AF trial is the first randomized study suggesting worse outcomes of LAA closure compared to medical therapy in high-risk atrial fibrillation patients. Key points: No difference in stroke …
December 31, 2025
The CINCH registry reports 5-year real-world outcomes of indirect mitral annuloplasty in patients with functional mitral regurgitation, demonstrating sustained clinical and echocardiographic improvement with a low rate of device- …
December 12, 2025
At Cardiology Update 2025 in London, I presented an evidence-focused overview of left atrial appendage (LAA) closure for stroke prevention in atrial fibrillation. The lecture summarized established clinical evidence …
December 1, 2025
Prof. Horst Sievert participated in the 25th CardioInterv congress in Curitiba (Brazil) and contributed to the scientific program with a lecture on new evidence in left atrial appendage (LAA) …
November 25, 2025
The long-awaited results of the CREST-2 trials were published in The New England Journal of Medicine on November 21, 2025. These data provide important new evidence on the management of asymptomatic high-grade …
November 20, 2025
At the 2025 VEITHsymposium in New York, Prof. Dr. Horst Sievert presented new clinical insights into the expanding field of multiorgan denervation — a novel endovascular approach that targets …
October 29, 2025
Frankfurt, Germany – October 2025 A live educational case from CVC Frankfurt was transmitted to the Transcatheter Cardiovascular Therapeutics (TCT) 2025 congress, illustrating the catheter-based closure of a residual …
October 27, 2025
San Francisco – October 27, 2025 Groundbreaking clinical experience with multi-organ denervation (targeting both hepatic and renal arteries) was presented at Transcatheter Cardiovascular Therapeutics (TCT) 2025. The presentation highlighted …
